Opinion

Video

Emerging Combinations in Maintenance Therapy for Ovarian Cancer

Panelists discuss how emerging maintenance strategies for advanced/metastatic disease increasingly focus on novel combination approaches, including immunotherapy combinations with PARP inhibitors (rucaparib + nivolumab), anti-angiogenic agents (atezolizumab + bevacizumab), and dual targeted therapy (olaparib + cediranib), with ongoing evaluation of optimal patient selection and sequencing in the treatment paradigm.

Video content above is prompted by the following:

What new maintenance strategies (eg, immunotherapy combination therapy or hormonal maintenance therapy) are being explored for advanced/metastatic disease?

  • Rucaparib + nivolumab
  • Atezolizumab + bevacizumab
  • Olaparib + cediranib
  • Where do these fit in the treatment paradigm?
  • In which patients may you consider these combination approaches?
Related Videos
5 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
5 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.